Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired ...

Neumora Therapeutics ( NMRA) shares crashed 80% to an all-time low Thursday when the biopharmaceutical firm announced that a ...

BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.

Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a ...

Royal Bank of Canada cut shares of Neumora Therapeutics (NASDAQ:NMRA – Free Report) from an outperform rating to a sector ...

Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -74.98%. The profit margin, also known as the revenue ratio or gross profit ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA) stock traded lower after the company released data from the Phase 3 KOASTAL-1 Study ...

Analyst Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Neumora Therapeutics, Inc. (NMRA – Research Report) and keeping the price ...

Whales with a lot of money to spend have taken a noticeably bearish stance on Neumora Therapeutics. If we consider the ...

Neumora Therapeutics Inc (NMRA) stock saw a modest uptick, ending the day at $2.17 which represents a slight increase of $0.20 or 10.15% from the prior close of $1.97. The stock opened at $2.23 and ...